Manufacturing, Cell Therapies

Boehringer Ingelheim Licenses Global Rights to Cystic Fibrosis Gene Therapy

August 06, 2018

Boehringer Ingelheim joins Oxford BioMedica, UK Cystic Fibrosis Gene Therapy Consortium, and Imperial Innovations to form a partnership for developing a new gene therapy to treat cystic fibrosis.

Gilead’s Kite, Gadeta to Develop Cell Therapies

August 01, 2018

The companies will work together to develop novel gamma delta T-cell receptor therapies in various cancers.

Novartis Has Production Hiccup for Kymriah CAR-T Therapy

July 19, 2018

The company has run into a snag in producing Kymriah for the diffuse large B-cell lymphoma patient population, the second indication for which the therapy was recently approved by FDA.

Novartis, CELLforCURE Partner to Manufacture CAR-T Therapies

July 18, 2018

CELLforCURE will produce cancer CAR-T treatments for Novartis at a manufacturing facility in Les Ulis (Essonne), France.

FDA Commissioner Gottlieb Releases Statement on Advancement of Gene Therapies

July 12, 2018

The agency is releasing six new draft guidances to provide a regulatory framework for handling gene therapies.

CellGenix Completes First Step of Facility Expansion for Cell-Culture Reagents

June 22, 2018

The company has completed the first phase of expansion at its headquarters in Freiburg, Germany, in anticipation of increasing demand as cell and gene therapies approach commercialization.

GE Healthcare Equips China Cell Therapy Manufacturing Plant with FlexFactory

June 07, 2018

The company will provide the first FlexFactory manufacturing platform for cell therapy manufacturing.

Lonza to Manufacture TxCell Product

June 01, 2018

TxCell announces manufacturing agreement with Lonza for its HLA-A2 CAR-Treg cellular product.

Bosch to Present New Freeze Dryer at Achema 2018

May 30, 2018

Bosch Packaging Technology will present its new modular freeze dryer at Achema 2018.

GE and CCRM Partner with DiscGenics on New Cell Therapy

May 30, 2018

GE Healthcare and the Centre for Commercialization of Regenerative Medicine (CCRM) will support scale-up efforts by DiscGenics for a new cell therapy intended to treat back pain.